AR097279A1 - Derivados de benzimidazolil-metil urea como agonistas del receptor de alx - Google Patents
Derivados de benzimidazolil-metil urea como agonistas del receptor de alxInfo
- Publication number
- AR097279A1 AR097279A1 ARP140102978A ARP140102978A AR097279A1 AR 097279 A1 AR097279 A1 AR 097279A1 AR P140102978 A ARP140102978 A AR P140102978A AR P140102978 A ARP140102978 A AR P140102978A AR 097279 A1 AR097279 A1 AR 097279A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- substituted once
- unsubstituted
- monocyclic
- Prior art date
Links
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 17
- 125000001424 substituent group Chemical group 0.000 abstract 11
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 10
- 229910052736 halogen Chemical group 0.000 abstract 9
- 150000002367 halogens Chemical group 0.000 abstract 9
- 125000002950 monocyclic group Chemical group 0.000 abstract 8
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 7
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000002619 bicyclic group Chemical group 0.000 abstract 4
- 125000004428 fluoroalkoxy group Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 cyano, hydroxy, dimethylamino Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1) donde n representa 0, 1, 2, 3, ó 4; D representa =N- o =C(R⁵)-; E representa =N- o =C(R⁴A)-; R⁹ representa alquilo C₁₋₄ o halógeno; R¹ representa alquilo C₁₋₄, alcoxi C₁₋₄, fluoroalquilo C₁₋₄, fluoroalcoxi C₁₋₄, ciano o halógeno; R² y R³ representan independientemente uno del otro hidrógeno o metilo; o R² y R³ forman, junto con el átomo de carbono al cual están unidos, un anillo cicloalquilo C₃₋₅ monocíclico; R⁴ y R⁴A representan independientemente uno del otro hidrógeno, alquilo C₁₋₄, alcoxi C₁₋₄, fluoroalquilo C₁₋₄, ciano, nitro o halógeno; R⁵ representa hidrógeno o halógeno; R⁶ representa hidrógeno o metilo; R⁷ representa hidrógeno, alquilo C₁₋₄ o hidroxi-alquilo C₁₋₄; R⁸ representa un grupo cicloalquilo C₃₋₈ mono- o bicíclico, dicho grupo está sin sustituir o está sustituido uno o dos veces, donde los sustituyentes son independientemente seleccionados del grupo que consiste en alquilo C₁₋₄, alcoxi C₁₋₄, hidroxi, hidroxi-alquilo C₁₋₄, halógeno, -COR¹⁰, y fenilo el cual está sin sustituir o está sustituido una o dos veces con alquilo C₁₋₄, fluoroalquilo C₁₋₄, halógeno, o -COOR¹¹; un grupo heterociclilo mono- o bicíclico, dicho grupo está sin sustituir; sustituido una vez en un átomo de nitrógeno con alquilo C₁₋₄, fluoroalquilo C₁₋₄, alquil C₁₋₄-carbonilo, alquil C₁₋₄-sulfonilo, fenil-alquilo C₁₋₄, cicloalquilo C₃₋₆ monocíclico o -COOR¹¹; sustituido una o dos veces en un átomo de carbono con flúor o oxo; o sustituido una, dos, tres, cuatro o cinco veces con metilo; un grupo cicloalquenilo C₅₋₆ monocíclico; un grupo arilo bicíclico parcialmente saturado o un grupo heteroarilo bicíclico parcialmente saturado, dichos grupos están independientemente sin sustituir o sustituidos una o dos veces, donde los sustituyentes son independientemente seleccionados del grupo que consiste en alcoxi C₁₋₄ y hidroxi; un grupo fenilo donde dicho grupo está sin sustituir o sustituido una vez con alcoxi C₁₋₄; un grupo heteroarilo monocíclico donde dicho grupo está sin sustituir o sustituido una o dos veces, donde los sustituyentes son independientemente seleccionados del grupo que consiste en alquilo C₁₋₄, cicloalquilo C₃₋₆ monocíclico, heteroarilo, bencilo y fenilo monocíclicos sin sustituir, donde el fenilo está sin sustituir o sustituido una o dos veces, donde los sustituyentes son independientemente seleccionados del grupo que consiste en alquilo C₁₋₄, alcoxi C₁₋₄, fluoroalcoxi C₁₋₄ y halógeno; un grupo alquilo C₄₋₆; o un grupo alquilo C₁₋₄ el cual está sustituido una vez con un sustituyente seleccionado del grupo X; sustituido una vez con un sustituyente seleccionado del grupo Y; sustituido dos veces con un sustituyente seleccionado del grupo X y un sustituyente seleccionado del grupo Y; o sustituido dos veces con un grupo heterociclilo monocíclico y un sustituyente seleccionado del grupo Y; donde X representa alcoxi C₁₋₄, fluoroalquilo C₁₋₄, ciano, hidroxi, dimetilamino, -COOR¹¹ o -CONH₂; Y representa un grupo cicloalquilo C₃₋₆ monocíclico, dicho grupo está sin sustituir o sustituido una vez con hidroxi o fenilo; un grupo heterociclilo monocíclico, dicho grupo está sin sustituir o está sustituido una vez en un átomo de nitrógeno con alquilo C₁₋₄, alquil C₁₋₄-carbonilo o -COOR¹¹; un grupo arilo bicíclico parcialmente saturado o un grupo heteroarilo bicíclico parcialmente saturado; un grupo arilo donde dicho grupo está sin sustituir o sustituido una, dos o tres veces, donde los sustituyentes son independientemente seleccionados del grupo que consiste en alquilo C₁₋₄, alcoxi C₁₋₄, alcoxi C₁₋₃-alquilo C₁₋₂, heterociclilo monocíclico-alquilo C₁₋₂, heteroarilo monocíclico -alquilo C₁₋₂, fluoroalquilo C₁₋₄, fluoroalcoxi C₁₋₄, ciano, halógeno, -COOR¹¹ y bis-(alquil C₁₋₂)-amino-alquilo C₁₋₂; o un grupo benzo[d][1,3]dioxolilo; o un grupo heteroarilo donde dicho grupo está sin sustituir o sustituido una o dos veces, donde los sustituyentes son independientemente seleccionados del grupo que consiste en alquilo C₁₋₄, cicloalquilo C₃₋₆ monocíclico, alcoxi C₁₋₄, fluoroalquilo C₁₋₄, fluoroalcoxi C₁₋₄, fluoroalcoxi C₁₋₄-alquilo C₁₋₂, halógeno, heterociclilo monocíclico y fenilo el cual está sin sustituir o sustituido una vez con alcoxi C₁₋₄; o R⁷ y R⁸ forman, junto con el átomo de nitrógeno al cual están unidos, un grupo heterociclilo mono- o bicíclico, dicho grupo está sin sustituir; o sustituido una vez en un átomo de nitrógeno con alquilo C₁₋₄, alquil C₁₋₄-carbonilo o -COOR¹¹; R¹⁰ representa hidroxi, alcoxi C₁₋₄ o amino; y R¹¹ representa alquilo C₁₋₄; o una sal de dicho compuesto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2013056530 | 2013-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097279A1 true AR097279A1 (es) | 2016-03-02 |
Family
ID=51688366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102978A AR097279A1 (es) | 2013-08-09 | 2014-08-07 | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9663473B2 (es) |
| EP (1) | EP3030560B1 (es) |
| JP (1) | JP6387411B2 (es) |
| KR (1) | KR20160042019A (es) |
| CN (1) | CN105473575B (es) |
| AR (1) | AR097279A1 (es) |
| AU (1) | AU2014304046B2 (es) |
| BR (1) | BR112016002459A8 (es) |
| CA (1) | CA2917954A1 (es) |
| ES (1) | ES2641172T3 (es) |
| MX (1) | MX2016001788A (es) |
| RU (1) | RU2016107974A (es) |
| TW (1) | TW201536756A (es) |
| WO (1) | WO2015019325A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR096686A1 (es) | 2013-06-25 | 2016-01-27 | Actelion Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx |
| ES2639798T3 (es) | 2013-07-18 | 2017-10-30 | Idorsia Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano con puente sustituidos con piperazina como agonistas del receptor ALX |
| ES2752733T3 (es) | 2013-11-28 | 2020-04-06 | Kyorin Seiyaku Kk | Derivados de urea deuterados o marcados isotópicamente o sales farmacológicamente aceptables de los mismos útiles como agonistas de FPRL-1 |
| WO2016189877A1 (en) | 2015-05-27 | 2016-12-01 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
| JP6746613B2 (ja) | 2015-05-27 | 2020-08-26 | 杏林製薬株式会社 | ウレア誘導体、またはその薬理学的に許容される塩 |
| ES3039644T3 (en) * | 2015-10-23 | 2025-10-23 | Vifor Int Ag | Novel ferroportin inhibitors |
| WO2017087318A1 (en) * | 2015-11-20 | 2017-05-26 | Mingsight Pharmaceuticals, Inc. | Treatment of autoimmune disease |
| KR20190068537A (ko) | 2016-09-18 | 2019-06-18 | 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 | Yap1과 oct4의 상호작용을 표적으로 하는 yap1 저해제 |
| JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| US20210147405A1 (en) * | 2017-06-14 | 2021-05-20 | European Molecular Biology Laboratory | Bicyclic heteroaromatic urea or carbamate compounds for use in therapy |
| CN108003048A (zh) * | 2017-12-07 | 2018-05-08 | 滨海吉尔多肽有限公司 | 一种o-甲基-苏/酪氨酸的制备方法 |
| CN111868052B (zh) | 2018-03-05 | 2024-03-08 | 百时美施贵宝公司 | 苯基吡咯烷酮甲酰肽2受体激动剂 |
| PE20211450A1 (es) | 2018-03-14 | 2021-08-05 | H Lee Moffitt Cancer Ct & Res | Inhibidores de yap1 que dirigen la interaccion de yap1 con oct4 |
| EP3870169A4 (en) * | 2018-10-23 | 2022-06-29 | The Brigham and Women's Hospital, Inc. | Lipoxin a4 analogs and uses thereof |
| CN112341451B (zh) * | 2019-08-09 | 2022-06-17 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN112341450B (zh) * | 2019-08-09 | 2022-05-17 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN114644577B (zh) * | 2020-12-18 | 2023-06-27 | 新发药业有限公司 | 一种取代异腈化合物的环保制备方法 |
| WO2024121709A1 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Papain-like protease (plpro) inhibitors |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407746A (en) | 1981-12-14 | 1983-10-04 | G. D. Searle & Co. | Cyclohexyl and phenyl substituted enkephalins |
| RU2106592C1 (ru) | 1996-07-12 | 1998-03-10 | Слипченко Николай Николаевич | Подводный спортивный пистолет |
| WO1998027108A2 (en) * | 1996-12-16 | 1998-06-25 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds and their use as nitric oxide synthase inhibitors |
| WO1999038867A1 (en) | 1998-01-29 | 1999-08-05 | Suntory Limited | 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phosphodiesterase iv inhibitory activity |
| US7087632B2 (en) | 2001-03-05 | 2006-08-08 | Transtech Pharma, Inc. | Benzimidazole derivatives as therapeutic agents |
| FR2822827B1 (fr) | 2001-03-28 | 2003-05-16 | Sanofi Synthelabo | Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant |
| DE10211770A1 (de) | 2002-03-14 | 2003-10-02 | Boehringer Ingelheim Pharma | Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US20050164305A1 (en) | 2002-04-03 | 2005-07-28 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| WO2004007459A2 (en) | 2002-07-12 | 2004-01-22 | Janssen Pharmaceutica N.V. | Naphthol, quinoline and isoquinoline-derivatives as modulators of vanilloid vr1 receptor |
| PE20040804A1 (es) | 2002-12-19 | 2004-12-31 | Boehringer Ingelheim Pharma | DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa |
| US7615568B2 (en) | 2003-05-30 | 2009-11-10 | Eli Lilly And Company | Antithrombotic ethers |
| US7141596B2 (en) | 2003-10-08 | 2006-11-28 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
| CN1894580A (zh) * | 2003-11-07 | 2007-01-10 | 阿卡蒂亚药品公司 | 脂氧素受体fprl1作为一种用于鉴定能有效治疗疼痛和炎症化合物的工具 |
| WO2005047899A2 (en) | 2003-11-07 | 2005-05-26 | Acadia Pharmaceuticals Inc. | Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation |
| US7371743B2 (en) | 2004-02-28 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Carboxylic acid amides, the preparation thereof and their use as medicaments |
| TW200538098A (en) | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| ATE546430T1 (de) | 2004-06-29 | 2012-03-15 | Aventis Pharma Inc | Fkbp bindende zusammensetzung und deren pharmazeutische verwendung |
| JP4885958B2 (ja) | 2005-08-12 | 2012-02-29 | エフ．ホフマン−ラ ロシュ アーゲー | フルオロ置換２−オキソアゼパン誘導体 |
| TW200902533A (en) | 2007-05-02 | 2009-01-16 | Boehringer Ingelheim Int | Carboxylic acid amides, manufacturing and use thereof as medicaments |
| JP2010536723A (ja) | 2007-08-16 | 2010-12-02 | エフ．ホフマン−ラ ロシュ アーゲー | 置換ヒダントイン |
| AR069650A1 (es) | 2007-12-14 | 2010-02-10 | Actelion Pharmaceuticals Ltd | Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano |
| DK2225231T3 (da) | 2007-12-18 | 2011-10-17 | Actelion Pharmaceuticals Ltd | Aminotriazolderivater som alx-agonister |
| EP2300427A1 (en) * | 2008-05-05 | 2011-03-30 | Amgen Inc. | Urea compounds as gamma secretase modulators |
| US8476470B2 (en) | 2008-08-07 | 2013-07-02 | Kyorin Pharmaceutical Co., Ltd. | Process for production of bicyclo[2.2.2]octylamine derivative |
| WO2010083246A1 (en) | 2009-01-15 | 2010-07-22 | Amgen Inc. | Fluoroisoquinoline substituted thiazole compounds and methods of use |
| JP5510945B2 (ja) | 2009-05-18 | 2014-06-04 | アクテリオン ファーマシューティカルズ リミテッド | Ａｌｘ受容体及び／又はｆｐｒｌ２アゴニストとしての架橋スピロ［２．４］ヘプタン誘導体 |
| JP5095035B2 (ja) | 2009-06-09 | 2012-12-12 | アクテリオン ファーマシューティカルズ リミテッド | フッ素化アミノトリアゾール誘導体 |
| ES2440790T3 (es) | 2009-06-12 | 2014-01-30 | Actelion Pharmaceuticals Ltd. | Derivados de oxazol y tiazol como agonistas del receptor del ALX |
| US9062076B2 (en) * | 2009-10-22 | 2015-06-23 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
| GB201009731D0 (en) | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
| US9187435B2 (en) | 2010-11-17 | 2015-11-17 | Actelion Pharmaceuticals Ltd. | Bridged Spiro[2.4]heptane ester derivatives |
| SI2649068T1 (sl) | 2010-12-07 | 2015-01-30 | Actelion Pharmaceuticals Ltd. | Derivati oksazolil-metiletra kot agonisti alx-receptorja |
| AR084172A1 (es) | 2010-12-07 | 2013-04-24 | Actelion Pharmaceuticals Ltd | Derivados aminotriazol hidroxilados como agonistas del receptor alx |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| JP5982001B2 (ja) | 2011-10-26 | 2016-08-31 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体モジュレーターとしてのｎ−尿素置換アミノ酸のアミド誘導体 |
| US8492556B2 (en) | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US8541577B2 (en) | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| MA37618B1 (fr) | 2012-05-16 | 2017-08-31 | Actelion Pharmaceuticals Ltd | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
| TW201348219A (zh) | 2012-05-16 | 2013-12-01 | Actelion Pharmaceuticals Ltd | 作爲ａｌｘ受體激動劑之經１－（對－甲苯基）環丙基取代橋聯螺［２．４］庚烷衍生物 |
| RU2696487C2 (ru) | 2013-03-06 | 2019-08-02 | Аллерган, Инк. | Применение агонистов формилпептидного рецептора 2 для лечения дерматологических заболеваний |
| CA2898301C (en) | 2013-03-06 | 2021-11-16 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
| AR096686A1 (es) | 2013-06-25 | 2016-01-27 | Actelion Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx |
| ES2639798T3 (es) | 2013-07-18 | 2017-10-30 | Idorsia Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano con puente sustituidos con piperazina como agonistas del receptor ALX |
| WO2015042071A1 (en) | 2013-09-19 | 2015-03-26 | Allergan, Inc. | Diphenyl urea derivatives as formyl peptide receptor modulators |
-
2014
- 2014-08-07 AR ARP140102978A patent/AR097279A1/es unknown
- 2014-08-08 MX MX2016001788A patent/MX2016001788A/es unknown
- 2014-08-08 RU RU2016107974A patent/RU2016107974A/ru unknown
- 2014-08-08 CN CN201480044332.8A patent/CN105473575B/zh not_active Expired - Fee Related
- 2014-08-08 ES ES14781943.7T patent/ES2641172T3/es active Active
- 2014-08-08 JP JP2016532785A patent/JP6387411B2/ja not_active Expired - Fee Related
- 2014-08-08 TW TW103127343A patent/TW201536756A/zh unknown
- 2014-08-08 EP EP14781943.7A patent/EP3030560B1/en not_active Not-in-force
- 2014-08-08 KR KR1020167006024A patent/KR20160042019A/ko not_active Withdrawn
- 2014-08-08 WO PCT/IB2014/063795 patent/WO2015019325A1/en not_active Ceased
- 2014-08-08 US US14/911,000 patent/US9663473B2/en not_active Expired - Fee Related
- 2014-08-08 AU AU2014304046A patent/AU2014304046B2/en not_active Ceased
- 2014-08-08 BR BR112016002459A patent/BR112016002459A8/pt not_active IP Right Cessation
- 2014-08-08 CA CA2917954A patent/CA2917954A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016107974A (ru) | 2017-09-15 |
| BR112016002459A2 (pt) | 2017-08-22 |
| TW201536756A (zh) | 2015-10-01 |
| US20160200686A1 (en) | 2016-07-14 |
| WO2015019325A1 (en) | 2015-02-12 |
| MX2016001788A (es) | 2016-05-18 |
| CN105473575B (zh) | 2017-11-24 |
| EP3030560B1 (en) | 2017-06-21 |
| KR20160042019A (ko) | 2016-04-18 |
| AU2014304046B2 (en) | 2018-07-05 |
| JP6387411B2 (ja) | 2018-09-05 |
| AU2014304046A1 (en) | 2016-03-17 |
| CA2917954A1 (en) | 2015-02-12 |
| EP3030560A1 (en) | 2016-06-15 |
| CN105473575A (zh) | 2016-04-06 |
| BR112016002459A8 (pt) | 2017-12-26 |
| US9663473B2 (en) | 2017-05-30 |
| JP2016529251A (ja) | 2016-09-23 |
| ES2641172T3 (es) | 2017-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR097279A1 (es) | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR093921A1 (es) | Derivados de indol carboxamida como antagonistas del receptor p2x7 | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| AR112348A1 (es) | Compuestos bicíclicos de pirazolo y triazolo como inhibidores de quinasas jak | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR093580A1 (es) | Inhibidores bmi-1 de pirimidina sustituidos | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| AR099789A1 (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR096788A1 (es) | Compuestos tricíclicos de carboxamida como inhibidores potentes de rock | |
| AR096450A1 (es) | Compuestos para la modulación de quinasas, y sus indicaciones | |
| AR100058A1 (es) | DERIVADOS DE PIRIMIDIN-PIRAZINAS FUSIONADAS MODULADORES DE RORg | |
| AR097936A1 (es) | Compuestos herbicidas | |
| AR098171A1 (es) | Piridinilimidazolonas como herbicidas | |
| AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| AR088630A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR087274A1 (es) | Derivados de amidas heterociclicas como antagonistas de receptores p2x7 | |
| AR110498A1 (es) | DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 | |
| AR106604A1 (es) | Compuestos de criptoficina y productos conjugados, su preparación y su uso terapéutico | |
| AR094053A1 (es) | Derivados de indol carboxamida como antagonistas del receptor p2x₇ | |
| AR091185A1 (es) | Derivados de 1,2,4-triazol | |
| AR101561A1 (es) | Nucleósidos de 2-cloro aminopirimidinona y pirimidina diona | |
| AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
| AR100776A1 (es) | Compuestos herbicidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |